Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
NEWS ALERT =shares worth more then $33 dollar '
Delcath Systems, Inc. (DCTH) approved to sell “In Europe, and we continue to make steady progress with the commercialization of CHEMOSAT.
“During the first three months of 2017 we continued to advance our clinical development programs in ocular melanoma liver metastases and intrahepatic cholangiocarcinoma, while making steady progress with commercialization of CHEMOSAT in Europe,” said Jennifer K. Simpson, Ph.D., MSN, CRNP President and CEO of Delcath.
“As we announced recently, we have concluded a new SPA agreement with the FDA for the initiation of a pivotal trial for the use of Melphalan/HDS in patients with ICC. This new trial will enroll approximately 295 ICC patients at about 40 clinical sites in the U.S. and Europe, with the primary endpoint of overall survival and with secondary and exploratory endpoints that include safety, progression-free survival, objective response rate and quality-of-life measures.
The trial is designed to be cost-effective and conducted in a financially prudent manner, with modest investment in this fiscal year. In conjunction with the FOCUS Trial in ocular melanoma liver metastases, our clinical development programs now include two paths toward potential U.S. market approvals.
“In Europe, we continue to make steady progress with the commercialization of CHEMOSAT. Our first quarter revenue of more than $0.7 million was double the prior year period’s sales, driven primarily by national reimbursement in Germany under the ZE system. With coverage under the ZE system now in place, we expect product sales growth from this market for the remainder of 2017. Elsewhere in Europe, we continue to focus on building the clinical and pharmacoeconomic data to support reimbursement applications in other key markets. We expect that positive negotiations for coverage in Germany will support our efforts for payment levels in other markets such as the U.K. and the Netherlands. Securing reimbursement coverage in additional European markets remains critical to future revenue growth for CHEMOSAT,” concluded Dr. Simpson.
First quarter 2017 revenue of $0.74 million, an increase of 100% compared with revenue of $0.37 million in prior year quarter;
CHEMOSAT treatment milestone set by SPIRE Southampton Hospital in the U.K. with more than 100 CHEMOSAT treatments performed, including eight treatments on a single patient;
Announced a Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug Administration (FDA) for the design of a pivotal trial of Melphalan/HDS to treat patients with intrahepatic cholangiocarcinoma (ICC);
NEWS ALERT! REVERS SPLIT R/S OFFICIALLY CONSOLED BY DIRECTORS.
(NASDAQ:DCTH) (the “Company”) announced today that its 2017 Annual Meeting of Stockholders (the “Annual Meeting”), scheduled for June 5, 2017, was convened and adjourned, without any business being conducted. The Annual Meeting has been adjourned until Friday, June 16, 2017 to allow more opportunity for stockholders to vote on all proposals described in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on May 5, 2017, including a proposal to approve an amendment to its amended and restated certificate of incorporation to effect a reverse stock split of its common stock, which the Company believes is vitally important to the Company’s future.
In Europe, our system has been commercially available since 2012 under the trade name Delcath Hepatic CHEMOSAT® Delivery System for Melphalan (CHEMOSAT), where it has been used at major medical centers to treat a wide range of cancers of the liver.
Best Analyses re"(DCTH) June 20, 2017
So far we’ve looked at the technical indicators that showcase the immediate and historical movement of the stock. Now it’s time to look at things over a longer time span. DCTH’s +0.07 has offered up a rich set of data upon which traders can base their expectations and indeed, their actions. Based on the reading, an overall sentiment has emerged and this can be said to be positive. A big reason for this has been the historical performance of the stock. Taken over a much broader base of measurement, DCTH has actually underperformed the S&P 500 by -114.01. This performance has created the perfect environment and now the stock has higher volatility levels compared to other companies in the same sector. To say that these readings and the inherent performance of the stock has placed it on the radar of many traders and analysts would indeed be an understatement. Interestingly enough, other factors are also playing their part in bolstering sentiments. This is especially so when you look at DCTH’s 406.14%. DCTH has an ATR reading of 25, suggesting much of what has already been established by the other technical factors. DCTH has made it very easy for traders to make up their minds; these are data sets that don’t get any clearer or compelling.
About Delcath Systems
Delcath Systems, Inc. is an interventional oncology Company focused on the treatment of primary and metastatic liver cancers. Our investigational product—Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS) —is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. We have commenced a global Phase 3 FOCUS clinical trial for Patients with Hepatic Dominant Ocular Melanoma (OM) and plan to initiate a Registration trial for intrahepatic cholangiocarcinoma (ICC) in the Fall of 2017. Melphalan/HDS has not been approved by the U.S. Food & Drug Administration (FDA) for sale in the U.S.
It seems to me (DCTH)' shares not be R/S= why shares will move higher , on other side III test pass FDA and selling already in Europe - I believe that market and day traders will analyse 'Delcath Systems, Inc. (DCTH)' and will find out that shares worth more then $25 dollars a share when a news regarding that fact that read below =
NEWS ALERT ! I found at FDA site that Delcath Systems, Inc. (DCTH) liver drag was approved by FDA, but management did not underline such great news= in order to depress share price /
Read below -and think how much (DCTH) shares relay worth visa-ave similar drag company which are trading over $32 dollars .
Percutaneous Hepatic Perfusion (PHP) vs. Cisplatin/Gemcitabine in Patients with Intrahepatic Cholangiocarcinoma - NCT03086993
In March 2017 we announced another SPA agreement with the FDA for the design of a new pivotal trial of Melphalan/HDS to treat patients with intrahepatic cholangiocarcinoma (ICC).
The pivotal trial is titled “A Randomized, Controlled Study to Compare the Efficacy, Safety and Pharmacokinetics of Melphalan/HDS Treatment Given Sequentially Following Cisplatin/Gemcitabine versus Cisplatin/Gemcitabine (Standard of Care) in Patients with Intrahepatic Cholangiocarcinoma .”
Under the SPA, the study will enroll approximately 295 ICC patients at approximately 40 clinical sites in the U.S. and Europe.
The primary endpoint is overall survival (OS) and secondary and exploratory endpoints include safety, progression-free survival (PFS), overall response rate (ORR) and quality-of-life measures. We expect to initiate the study in the Fall of 2017.
This pivotal study in ICC is designed to be cost effective and pursued in a financially prudent manner. Given the sequential nature of the trial design, our investment in this study will be modest in 2017 as the Melphalan/HDS segment of the study will not occur until late in the year.
The SPA agreement for this trial indicates that the pivotal trial design adequately addresses objectives that, if met, would support regulatory requirements for approval of Melphalan/HDS in ICC.
All indicators is green= pointing out we will open mach higher .
It is good pr-market low value sold , because usually if large value and price is mach higher , then at opening day traders will dump shares in order to make money .
NEWS ALERT ! I found at FDA site that Delcath Systems, Inc. (DCTH) liver drag was approved by FDA, but management did not underline such great news= in order to depress share price /
Read below -and think how much (DCTH) shares relay worth visa-ave similar drag company which are trading over $32 dollars .
Percutaneous Hepatic Perfusion (PHP) vs. Cisplatin/Gemcitabine in Patients with Intrahepatic Cholangiocarcinoma - NCT03086993
In March 2017 we announced another SPA agreement with the FDA for the design of a new pivotal trial of Melphalan/HDS to treat patients with intrahepatic cholangiocarcinoma (ICC).
The pivotal trial is titled “A Randomized, Controlled Study to Compare the Efficacy, Safety and Pharmacokinetics of Melphalan/HDS Treatment Given Sequentially Following Cisplatin/Gemcitabine versus Cisplatin/Gemcitabine (Standard of Care) in Patients with Intrahepatic Cholangiocarcinoma .”
Under the SPA, the study will enroll approximately 295 ICC patients at approximately 40 clinical sites in the U.S. and Europe.
The primary endpoint is overall survival (OS) and secondary and exploratory endpoints include safety, progression-free survival (PFS), overall response rate (ORR) and quality-of-life measures. We expect to initiate the study in the Fall of 2017.
This pivotal study in ICC is designed to be cost effective and pursued in a financially prudent manner. Given the sequential nature of the trial design, our investment in this study will be modest in 2017 as the Melphalan/HDS segment of the study will not occur until late in the year.
The SPA agreement for this trial indicates that the pivotal trial design adequately addresses objectives that, if met, would support regulatory requirements for approval of Melphalan/HDS in ICC.
It seems to me (DCTH)' shares not be R/S= why shares will move higher , on other side III test pass FDA and selling already in Europe - I believe that market and day traders will analyse 'Delcath Systems, Inc. (DCTH)' and will find out that shares worth more then $25 dollars a share when a news regarding that fact that read below =
About Delcath Systems
Delcath Systems, Inc. is an interventional oncology Company focused on the treatment of primary and metastatic liver cancers. Our investigational product—Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS) —is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. We have commenced a global Phase 3 FOCUS clinical trial for Patients with Hepatic Dominant Ocular Melanoma (OM) and plan to initiate a Registration trial for intrahepatic cholangiocarcinoma (ICC) in the Fall of 2017. Melphalan/HDS has not been approved by the U.S. Food & Drug Administration (FDA) for sale in the U.S.
In Europe, our system has been commercially available since 2012 under the trade name Delcath Hepatic CHEMOSAT® Delivery System for Melphalan (CHEMOSAT), where it has been used at major medical centers to treat a wide range of cancers of the liver.
Best Analyses re"(DCTH) June 20, 2017
So far we’ve looked at the technical indicators that showcase the immediate and historical movement of the stock. Now it’s time to look at things over a longer time span. DCTH’s +0.07 has offered up a rich set of data upon which traders can base their expectations and indeed, their actions. Based on the reading, an overall sentiment has emerged and this can be said to be positive. A big reason for this has been the historical performance of the stock. Taken over a much broader base of measurement, DCTH has actually underperformed the S&P 500 by -114.01. This performance has created the perfect environment and now the stock has higher volatility levels compared to other companies in the same sector. To say that these readings and the inherent performance of the stock has placed it on the radar of many traders and analysts would indeed be an understatement. Interestingly enough, other factors are also playing their part in bolstering sentiments. This is especially so when you look at DCTH’s 406.14%. DCTH has an ATR reading of 25, suggesting much of what has already been established by the other technical factors. DCTH has made it very easy for traders to make up their minds; these are data sets that don’t get any clearer or compelling.
TODAY SHARES GO UP TO 0.49
LUNCH TIME OVER SHARE GO UP TO 0.49
1 share to 500 shares revers split read fillings below -STRONG SELL
https://ih.advfn.com/p.php?pid=nmona&article=74517464
1-500 shares reverse stock split
STRONG SELL- 1-500 shares reverse stock split of our common stock
(5) To approve an amendment to our amended and restated certificate of incorporation to effect a reverse stock split of our common stock, such split to combine a whole number of outstanding shares of our common stock in a range of not less than fifty shares and not more than five hundred shares, into one share of common stock in the discretion of the Board of Directors, and to grant authorization to the Board of Directors to determine, in its sole discretion, whether to implement the reverse stock split, as well as its specific timing; and
NEWS-SATELLITE INTERCEPTION
Our advanced satellite interception systems cover most of the major satellite systems: Iridium, Thuraya and IsatPhone Pro.
Ability provides tactical and strategic interception systems for Thuraya, Iridium and IsatPhone Pro, along with systems to intercept VSAT, DCME and other satellite links.
We offer tactical interception systems for Thuraya, Iridium and IsatPhone Pro, that intercept voice calls, SMS, data traffic, call related information and can detect the location of satellite phones. The interception is done by obtaining and decoding the traffic between users’ devices and the respective satellites. Due to the system’s lightweight, low-energy consumption and minimal maintenance requirements, they can be installed on airborne platforms.
An API for easy integration with larger intelligence systems is also available.
In addition, Ability also offers strategic solutions for Thuraya and IsatPhone Pro interception and a Satellite Link Interception System (SLIS).The SLIS monitors information transmitted through satellite communication channels such as VSAT, DCME coming from Intelsat, Eutelsat, Arabsat, Domsat, Indosat and other global or regional satellite communication operators.
http://www.interceptors.com/satellite-interception/
STRONG BUY -NEW MILITARY CONTRACT SIGHED $$$$$$
BUY ALERT -Chief Executive Officer, Bill Welch, will be presenting The Marcum 2017 MicroCap Conference On June 15 In New York City
Trovagene, Inc. (NASDAQ:TROV), a precision medicine biotechnology company, today announced that its Chief Executive Officer, Bill Welch, will be presenting at the Marcum 2017 MicroCap Conference on June 15, 2017 at 3:00 PM EDT at the Grand Hyatt Hotel in Julliard on the conference
level. Management will also be available to meet with investors during the conference.
https://www.barchart.com/stocks/quotes/TROV/news#/news/2514410/trovagene-to-present-at-the-marcum-2017-microcap-conference-on-june-15-in-new-york-city
News Alert ! Novavax RSV F Vaccine Phase 2 Clinical Trial Data in Women of Child Bearing Age Published in Vaccine
PR Newswire PR NewswireJune 7, 2017CommentGAITHERSBURG, Md., June 7, 2017 /PRNewswire/ -- Novavax, Inc., (NVAX) today announced that data from the second of two Phase 2 trials of its RSV F protein recombinant nanoparticle vaccine candidate (RSV F Vaccine) in women of child bearing age have been published in the journal Vaccine (the data contained in this publication have been shared in prior scientific conferences). The Company previously announced top line results from this trial in April 2014. Novavax is developing the RSV F Vaccine with the goal of protecting infants from RSV disease.
https://finance.yahoo.com/news/novavax-rsv-f-vaccine-phase-120500126.html
STRONG UPTREND NOW - $2-$3
Strong Buy =We gonna see at list $150 up=( if you read sell agreement in 8k filling NIHD sold it shares for $3.80 a share its 40% Brazilian internet and Mobil market full price was $280 million dollars its coming $3.80 NIHD a share .
For Mexican market is is an additional $150 mullion / 40% its Mexican internet and Mobil market .ONLY WAY UP .
Strong Buy =open at $1.25 a share =BUY-BUY-BUY AS MUCH YOU CAN-
In week time we see over $2.00 a share. All green / Get Reach-WOW!!!
Strong buy (OCRX)-good news coming at June 2, 2017 at 11.00 am .
Time to get more shares . Good luck to all.
Strong Buy New management looking to get NIHD share price over $1.15 in a week time and hold a 10 days as requested under Nasdaq regulations.
P.S.(NIHD) never reversed it shares = only get incensed 1-3 shares in their history .
It is imported to Now.
Strong Buy New management looking to get NIHD share price over $1.15 in a week time and hold a 10 days as requested under Nasdaq regulations.
P.S.(NIHD) never reversed it shares = only get incensed 1-3 shares in their history .
It is imported to Now.
BUY-BUY-BUY In this price ever able to buy/. Why shares vent down = ex- Director sold his shares over 2,000,000. million share in tow hours- look at information news 13Q 31 May, 2017 there is stated . I should look but choose to buy .Good luck to All .
BUY as you can .
https://ih.advfn.com/p.php?pid=nmona&article=74830870
Strong Buy New management looking to get NIHD share price over $1.15 in a week time and hold a 10 days as requested under Nasdaq regulations.
P.S.(NIHD) never reversed it shares = only get incensed 1-3 shares in their history .
It is imported to Now.
BUY-BUY-BUY In this price ever able to buy/. Why shares vent down = ex- Director sold his shares over 2,000,000. million share in tow hours- look at information news 13Q 31 May, 2017 there is stated . I should look but choose to buy .Good luck to All .
BUY as you can .
Strong buy (ocrx)-good news coming at June 2, 2017 at 11.00 am .
Time to get more shares . Good luck to all.
NEWS ALERT-SOMEBODY BUYING ( NIHD ) INTERNET PROVIDER -MOBIL PHONE OPERATOR
in SOUTH AMERICA -PANAMA-COLUMBIA-BRAZIL =OVER $389 million Revenue a year worth over $ 7.50 a share 1 year a go trading less $ 0.90 only will go UP.
STRONG BUY !
STRONG BUY ! (FNCX) I believe the management decided stay on NASDAQ will push (FNCX) shares over $1.15 a share .
BUY More as you can as I did . Good luck to all.
15:09:13 $ .6999 12,952
Delay Q1 which coming any time due that a (FNCX) maid a profit in Q 1 or much better results which kick (FNCX) share over a $1.15 a share any time .
STRONG BUY (NVAX) all indicators pointing out shares open $ 1.10 -$1.25 good news is coming any time.
STRONG BUY (CYRN) Revenue UP - New exclusive security platform with new antivirus program developed.
All indicators showing (CYRN) Green all the way UP to the $3.25 at closing - opening at $3.75-$4.50 .
-STRONG BUY- BUY- BUY- WE GET TO$1.32 TODAY ! GET REACH
STRONG BUY = and Why BUY- BUY- BUY in this low price .
It is good thing that FNCX did not do reveres split in order to qualify to stay at NASDAQ required that shares must be traded over $1 more then 90 days strait .
The FNCX choose to sell it shares for premium price (when shares traded $0.65 a share ) at $ 1.05 a share =pointing out, that investors who bought the shares FNCX knows sum facts we do not know right now.
That FNCX shares worth more then $3.50 after 1st Q will be relised where FNCX will show profits.
This facts will trigger FNCX shares to the roof .
I believe more or less $3.50 a shares.
Fact #2 Farther more some one who knows more then we do bought after hour trading at 16:05:38 paid for FNCX share a $ 0.8037 159,000 shares paying premium over $ 0.10c check it out.
I hope you all agree that some good should be seen soon.
Thank you to red my thoughts, but you all should make your own choice. It is your money.
http://www.nasdaq.com/symbol/fncx/after-hours
Strong Buy FAlert! IFON- we going only up over $1.50 a share = IFON shares so chip -BUY as many you can !
Strong Sell
-STRONG BUY =Good News- WE ARE GOING UP TODAY~ AEterna Zentaris Inc. (AEZS) PT Set at $2.00 by Maxim Group
The company’s revenue for the quarter was up 200.0% on a year-over-year basis. During the same period in the prior year, the firm earned ($1.46) EPS. Equities analysts anticipate that AEterna Zentaris will post ($1.06) EPS for the current fiscal year.
Posted by Shayan Afkhami on May 3rd, 2017 //
https://www.mideasttime.com/aeterna-zentaris-inc-aezs-pt-set-at-2-00-by-maxim-group/1655686.html
STRONG BUY-(FDA) has reached an agreement with CytRx on preparations for a New Drug Application (NDA) submission for aldoxorubicin in soft tissue sarcomas (STS). STS remains a high unmet medical need.
RISK-TAKER you do what ever you think it is your money !
Instead to thank me for the tip -you are accusing me that I am 70 years old Vet a pamper? –You think that I had in my mind, that on this board you and others loos you savings , so I able to gain?
Did I lie the shares not reach a 200% gain in past 5 days?
For such fallacious accusation in US army getting lots a biting, even we break a leg.
Today 19 of April 2017 I sold my shares ARGS Check it out . Good luck to all.
09:59:11 $ .7443 18,600
$ARGS =STRONG SELL =ONLY GOING DOWN-GOOD LUCK
BUY ALERT! $1.25 -$1.35 !(((((OCRX ((( TIME TO BUY -I JUST GET $1.35 20000 a shares -
Recommend to buy for kids (( HLTH )) =this one is real =Good Luck